Abdominal Hysterectomy (TAH) for stage I endometrial cancer (LACE) randomised controlled trial was initiated in 2005. The primary objective of stage 1 was to assess whether TLH results in equivalent or improved QoL up to 6 months after surgery compared to TAH.
Introduction
Endometrial cancer is the most common gynaecological malignancy in developed countries and 80% will be diagnosed at early stages 1 or 2 (1, 2). Primary treatment of early-stage endometrial cancer is surgical and includes a total hysterectomy, bilateral salpingooophorectomy, with or without pelvic and aortic lymph node dissection (3) . Traditionally, an extrafascial total abdominal hysterectomy (TAH) has been performed through a laparotomy in most centres worldwide (4, 5) . However laparoscopic hysterectomy techniques have gained popularity in recent years as summarised in two systematic reviews and one metaanalysis (6) (7) (8) (9) . Laparoscopic Assisted Vaginal Hysterectomy (LAVH) has been associated with less tissue trauma, lower estimated blood loss, less pain, shorter hospital stay, and less time off work compared to TAH (10) (11) (12) (13) (14) (15) . A further potential advantage of laparoscopic techniques over TAH is improved quality of life (QoL) post-surgery. A small trial comparing QoL following LAVH or TAH (15) found that the laparoscopic group had significantly better QoL values at one, three, and six months post-surgery. In a recent Gynecologic Oncology Group (GOG LAP-2) trial, patients in the laparoscopy group (various laparoscopy-assisted procedures allowed) had superior short-term QoL outcomes compared to the TAH group up to six weeks post-surgery, but by six months both groups had similar QoL except for body image in favour of the laparoscopic procedure (16) . The focus of the present study is on Total Laparoscopic Hysterectomy (TLH). Compared to previous laparoscopic techniques TLH represents a new and innovative approach, as the procedure can be completed entirely laparoscopically without the need for a vaginal surgical phase (17) .
To collect high quality outcome data for this new surgical procedure (18) , we initiated a twostage international phase 3 multi-centre randomised-controlled surgical trial. The primary objective of stage 1 was to test the hypothesis that TLH results in equivalent or improved QoL up to 6 months after surgery compared to TAH. The primary objective of stage 2 was to test the hypothesis that disease-free survival at 4.5 years is equivalent for TLH and TAH.
Results addressing the primary objective of stage 1 are presented here.
Methods
The trial was initiated in 2005, registered with clinicaltrials.gov (NCT00096408) and the Australian New Zealand Clinical Trials Registry (CTRN12606000261516), and approved by all relevant hospital and university ethics committees. The protocol can be found http://www.gyncan.org/page/attachment/24/lace-protocol-v6-march-2009. Trial design: A detailed description of the study methods including details of the two surgical approaches has been published previously (19) . In brief, we followed a two-stage clinical trial design. During the formal QoL substudy we randomised 361 patients into TLH versus TAH to assess QoL. To establish the feasibility of enrolment and to maximise the evidence for the new procedure, a 2:1 randomisation scheme was used for the first 180 patients, followed by 1:1 allocation for all remaining patients. Following on from stage 1, another 575 patients were enrolled for a total of 755 patients (completion June 2010) randomisation.
Eligibility criteria: Patients were recruited through one of 19 participating tertiary gynaecological cancer centres in Australia, New Zealand, and Hong Kong. Women were eligible if they were older than 18 years, with histologically confirmed stage 1 endometrioid endometrial adenocarcinoma (irrespective of histological grade) and ECOG performance status <2. Patients had to have a CT scan of the abdomen and the pelvis suggesting the absence of extrauterine disease in the abdomen, and a chest X-Ray or a CT scan of the chest to suggest absence of pulmonary metastasis. All patients provided written informed consent.
Patients were excluded if they met any of the following conditions: histological cell type other than endometrioid on curettings, clinically advanced disease (stage 2 to 4) or bulky lymph nodes based on imaging, uterine size larger than 10 weeks of gestation, estimated life expectancy less than 6 months, medically unfit for surgery, patient compliance and geographic proximity not allowing adequate follow-up, or unfit to complete QoL assessments. The FIGO 2009 staging classification was used (20) .
Randomisation and masking: Randomisation using stratified permuted blocks was carried out centrally and independent from other study procedures through a web-based system at the University of Queensland, ascertaining concealment of the next allocated treatment to study staff. During stage 1 of the trial, randomised permuted blocks were used to allocate patients between the two treatment groups with an allocation ratio of 2:1, favouring the intervention of TLH (mixed blocks of sizes 3 and 6). Randomisation was stratified according to treating centre and by grade of differentiation (as taken from the endometrial biopsy/D&C).
The 2:1 randomisation was initially selected in order to gain insight into the new laparoscopic procedure. As a result, enrolment was above expectations and the trial was attractive for granting bodies offering seed funds, which allowed us to apply for substantial funding for stage 2 of the LACE trial evaluating the two surgical procedures in an equivalence trial design with respect to survival. When funding for the larger study was secured, the randomisation reverted to 1:1 but it was also felt that the QoL study should continue to a sample size of 360. After 180 patients were randomised the programme was adjusted to allow a 1:1 randomisation stratified according to treating centre, grade of differentiation and history of cancer but not to be influenced by the 2:1 imbalance in the strata.
All surgeons on the trial had to be accredited gynaecological oncologists, had to complete at least 20 TLHs, had to submit video footage about a TLH, and finally had to perform a TLH live in the presence of a senior accredited surgeon. Surgeons discussed the study with the patients and obtained informed consent. Study staff then completed baseline assessments and obtained the allocated treatment via the web-based case report system. Blinding was not possible due to ethical considerations and the nature of the treatment.
Surgical technique: The surgical procedures have been described in detail previously (19) .
Briefly, TLH is a four-point laparoscopic procedure. A silicone tube with a diameter of 45 or 35mm and a lid on its outer end is inserted transvaginally (McCartney Transvaginal tube®), and aids reflecting the bladder peritoneum, outlining the vaginal fornices, securing the uterine vessels laparoscopically and finally acts as a conduit to remove the specimens from the patient. The vaginal vault was sutured laparoscopically.
Surgeons were required to perform pelvic ± para-aortic lymph node dissection as part of the treatment in both arms. However a lymph node dissection could be omitted if any of the following criteria were met: morbid obesity, well-differentiated or moderately differentiated tumours invading only to the inner half of the myometrium, or medically unfit for lymph node dissection.
Conversion from assigned treatment was noted in 8/332 cases (2.4%). Of these, 1/332 patient changed from TAH to TLH after randomisation due to patient preference, while 7/332 changed from TLH to TAH (five for anatomical reasons preventing the completion of TLH; one due to intra-operative complications; and one patient was found to have advanced disease).
Baseline assessments were performed before randomisation (up to 28 days prior to surgery), collecting demographic information, height and weight, and QoL data. Follow-up assessments for QoL and short-term surgical outcomes were performed at 1 week, 4 weeks, 3 months, and 6 months post-surgery (± 3 days), to assess early (up to 4 week) and late (up to 6 months) post-surgical recovery, respectively.
Quality of Life Measurements
The primary outcome measure of QoL was the Functional Assessment of Cancer Therapy-General (FACT-G) Version 4 questionnaire (21) . Patients raw scores on the physical (PWB) (7 items, range: 0-28), social (SWB) (7 items, range: 0-28), emotional (EWB) (6 items, range: 0-24), and functional (FWB) (7 items, range: 0-28) well-being subscales were measured (22) . Patients also completed a 17-item endometrial subscale, which together with the FACT-G forms the FACT-Endometrial (EnWB). All subscales and summary scores were recoded and scored according to standard FACT scoring algorithms such that higher scores indicate better QoL (22) .
Body Image Scale
The Body Image Scale is a ten-item scale designed for cancer patients. The ten items were rated on a 0-3 scale (0 = "not at all", 1= "a little", 2= "quite a bit", 3 = "very much") and summed to produce an overall summary score ranging from 0 (best body imageno symptoms or distress) to 30 (worst body image) (23) .
EuroQoL five dimensions (EQ-5D)
The EQ-5D is a simple measure of generic QoL. It allows patients to rate their overall health on a visual analogue scale of 1-100 (EuroQoL-VAS) (24) which was used for the present analysis.
For ease of interpretation all QoL scales were subsequently transformed to 0-100 scales with higher scores indicating better QoL (25) . Based on the literature a 5% difference or more in the QOL scores were predefined as clinically significant (26) (27) (28) . Difference scores were calculated to assess change in QOL from baseline (pre-surgery). Forest plots (see statistical analysis) were used to represent early and late recovery of QoL from baseline and assess the relative recovery comparing TLH to TAH treated patients, with positive values favouring TLH.
Documentation of surgery details, adverse events and length of hospital stay (LOS)
Pre-existing surgical and medical history was taken prior to surgery. After surgery, patients were assessed on a daily basis by their gynaecological oncologist until discharge from hospital. Surgical outcomes including length of operating time, intraoperative complications, cross-overs (e.g., conversion to laparotomy) and reasons for conversion, were documented immediately following surgery. Intraoperative injuries were coded in the categories of visceral injury, blood transfusion, uterus rupture, vaginal laceration or vascular injury. Postoperative adverse events (AEs) were recorded at predefined time points up to six months using the NCI Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Serious AEs were defined as any event that resulted in death, was immediately life threatening, required inpatient hospitalization or prolongation of an existing hospitalization or that resulted in persistent or significant disability/incapacity. Length of hospital stay (LOS) was measured from the day after surgery (day 1) to discharge. Length of operating time was measured from skin incision to completion of wound closure.
Statistical analysis
Sample size: For the stage I QoL component, recruitment commenced in 2005 with a 2:1 randomisation scheme. For the QoL outcomes, aassuming 80% power, 10% overall noncompliance, a 5% type I error rate (95% confidence level) and a 2-tailed comparison, a sample size of at least 180 patients (120 allocated to TLH, 60 patients to TAH) was estimated to detect a 10% difference (and standard deviation of 20) in the FACT-G between intervention and control group participants (26) . However, when literature suggested a 5% difference in QoL to be clinically important (27) (28) (29) the collection of QoL data was extended to include 361 patients, (and standard deviation revised from 20 to 16.9 units).
QoL over time was analysed by computing change scores between baseline measurements and each post-operative time point measurement. The primary endpoint for the QoL analysis was the difference between the groups in QoL changes from baseline. The main analysis was broken into two parts, early (1 and 4 weeks) and late (3 and 6 months) for each QoL variable.
Differences in change scores between the TAH and TLH were then compared separately for early and late recovery periods using Generalized Estimating Equations (GEE), with an exchangeable correlation structure to account for repeated measures. This method enables the inclusion of observations from subjects who have either dropped out or have intermittent missing data (30) . Mean group differences between TAH and TLH, together with the 95% confidence intervals (95% CI), for each of the QoL domains were compiled, with positive percent differences representing an absolute advantage for the TLH group compared to TAH and were presented in a forest plot. Differences were considered statistically significant if the p-value was less than 0.05. No adjustment for multiple comparisons were made, and as such, the results should be viewed with some caution with special attention to the size of any difference, the plausible range (95% CI) of this difference together with any relevant clinical benefit rather than just the statistical p-value.
FACT-G change scores were used to examine QoL improvement over time. Early recovery in QoL was derived by taking the maximum improvement from weeks 1 and 4 measurements, except where the participant had not completed measurements at both time points, in which case the single available measurement was used. The maximum improvement was then dichotomized in a number of different ways showing at least 5%, 10%, 15% and 20% improvement. Contingency tables were then used to compare improvement for TAH and TLH, and chi square tests were used to assess difference between the groups. In a similar way, late recovery in QoL was derived by using the change scores at 3 and 6 months. Missing value patterns were investigated by examining the association of baseline variable using univariate and multivariate logistic models to the presence of missing QoL outcomes for both the early and late periods (30) . All comparisons between groups were evaluated on an intention-to-treat principle. SAS™ statistical software, version 9.1 (31) and
ACCoRD, version 1.68 (32) was used. All comparisons are two-sided with a nominal significance level of 5%.
Role of the funding source
The study sponsors had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results
In total, 784 patients were screened for inclusion between October 7, 2005 (Figure 1) . Patients randomised to TAH or TLH had similar demographic characteristics but patients assigned to TAH had better QoL at baseline (although most confidence intervals overlapped) (Table 1) .
Patients treatment characteristic are reported in Table 2 . Patients who had a TLH were less likely to have received a lymph node dissection for surgical staging purposes ( Table 2) . A significantly higher proportion of patients who were assigned to TAH stayed in hospital for 2 days or more (139/142 after TAH compared to 72/190 after TLH, p<0.0001). The median (IQR) time to surgery was 7 (4-13) days for TAH and 7 (4-13) days for TLH (p= 0.90). were noted in functional well-being (13% greater improvement for patients with TLH), followed by physical well-being (11% greater), endometrial cancer-specific well-being (6% greater) and overall FACT-G summary score (7% greater) (p=0.001 for all comparisons).
Quality of Life recovery
Patients with TLH also reported 5% (p=0.001) greater improvements in their body image and 7.5% (p=0.001) in overall QoL (EQ-VAS) compared to patients with TAH. There was no significant difference during early recovery in emotional (p=0.39) or social wellbeing (p=0.59) between patients assigned TAH or TLH. During the late post-operative recovery phase (3 to 6 months post surgery), patients with TLH compared to patients with TAH recovered significantly more in their physical (p=0.008), functional (p=0.009), endometrial cancer-specific (p=0.003), and overall well-being (FACT-G) (p = 0.03), and also experienced superior QoL recovery with regards to body image (p=0.001).
There was an imbalance in the number of lymph node dissections (LND) performed between the two treatments. Patients who received LND had significantly lower QoL in FWB and FACT-G at early recovery (1 to 4 weeks postoperatively) compared to those without LND.
QoL was not different in all other subscales and in any subscales at late recovery (3 to 6 months postoperatively). LND was significantly related to FACT-G (p=0.01) and FWB (p=0.04) at early recovery, with treatment remaining highly significant in favour of TLH even after adjustment for LND. For all other subscales and all subscales at late recovery there was no significant interaction between LND and treatment allocation. (Table 3 ). This table also shows that the improvement in the FACT-G is maintained as the clinical threshold is increased and is maintained at the late recovery period.
The number of women with completely missing QoL assessments was low, from 8/332 (2.4%) at baseline increasing to 42/332 (12.7%) at six months post-surgery. Overall, 263/332 (79.2%) of participants provided data at all five time points, and a further 30/332 (9%) completed measures at all but one timepoint. A higher proportion of patients assigned to TAH compared to TLH did not complete any QoL forms at 1 week (12/142 (8.5%) versus 4/190 (2.1%), and 6 months (24/142 (16.9%) versus 18/190 (9.5%), post surgery.
The proportion of missing values data at the 5%, 10% 15% and 20% differences in the FACT-G scale was 6% (12/190) in the TLH and 14% (20/142) in the TAH group. This imbalance was investigated further to determine whether there was any signal of a systematic pattern in the missing values during the early and late periods, we examined the association of the baseline variables: Age, obesity, grade, ECOG, lymph node dissection and whether there was a correlation with the FACT-G changes being missing. No such patterns were found in either the early or late missing periods in a univariate or multivariate logistic analysis, other than a treatment imbalance. There was no significant interaction between treatment and these variables on whether the response was missing suggesting that any systematic pattern which could be present would be well within the play of chance. The missing data patterns for the other outcomes were similar (i.e. no discernable trend).
Surgical and short term outcomes
Length of operating time was significantly longer in the TLH group (138±43 mins), than in the TAH group at (109±34 mins; p=0.001). There was no significant difference in numbers of patients with intraoperative adverse events between the TLH (14/190,7 .4%) and TAH (8/142,5.6%) groups (p = 0.55). Two patients had an SAE intraoperatively (one TLH, one TAH). The first patient experienced an inadvertent cystostomy at TLH, resulting in prolonged hospitalisation. The second patient, in the TAH group, had a rotten tooth knocked out during intubation, causing oropharyngeal bleeding resulting in a difficult endotracheal intubation. This patient was transferred to the Intensive Care Unit postoperatively for monitoring. Postoperatively, more than twice as many patients in the TAH group experienced AEs CTC grade 3+ than in the TLH group (33/142, 23.2% and 22/190, 11 .6% respectively; p=0.004). Postoperative serious AEs occurred more frequently in patients who had a TAH (27/142, 19 .0%) than a TLH (15/190, 7 .9%) (p=0.002). Specific complications are presented in Table 4 . No treatment-related patient deaths were recorded.
The mean haemoglobin decline from pre-surgery to first day post-surgery was 1.8±1.1 g/dL in the TLH group and 2.1±1.1 g/dL in the TAH group (p = 0.013). A larger proportion of patients stayed at hospital post-surgery for 2 days or more after TAH (139/141, 98.6%) compared to patients after TLH (72/191, 37.7%) (p<0.0001). that patients who had a TLH return to normal activities more quickly, which seems especially relevant given the ageing of the population (33) . A larger proportion of patients treated with TLH had improvements of 5% or more from baseline QoL during the early and late recovery after surgery for endometrial cancer.
Discussion
To date, two prospective clinical trials compared QoL following laparoscopic and open surgery using a validated self-reported QoL scale, although neither studied TLH specifically (15, 16) . An Italian trial randomised 84 patients comparing LAVH with TAH and found that patients treated with LAVH had significantly better overall QoL at four weeks, three and six months post-surgery, compared to patients treated with open surgery (15) , which is similar to the more prolonged improvement of QoL found in the current study. dissection in all patients regardless of pre-or intraoperative findings. The need for a full pelvic and aortic node dissection was the most common reason for conversion to laparotomy in LAP-2. In the LACE trial, surgeons were also required to perform pelvic ± para-aortic lymph node dissection as part of the treatment in both arms but they could elect to omit a lymph node dissection if patients met specific criteria as outlined above. In LACE, 52% of patients had a pelvic and/or aortic lymph node dissection, which is comparable with previous reports (35) . However, a lower proportion of patients receiving TLH than TAH underwent a lymph node dissection, which may have contributed to better QoL outcomes in the laparoscopic group in the early phase of surgical recovery. Indeed, when we assessed the effect of lymph node dissection on QoL outcomes adjusted for treatment received, LND only influenced FACT-G and FWB at early recovery.
Another reason for the good QoL results in the TLH group could be that the LACE trial started enrolment later than the LAP-2 trial and the trial management committee made an enormous effort to ascertain that all surgeons were beyond their individual learning curve. All surgeons had to complete 20 unsupervised TLH procedures, had to submit video footage of one procedure, which qualified them to perform a live TLH and node dissection, which was witnessed by one of the senior LACE trial surgeons attending in person. Comparing QoL scores from early enrolment to QoL scores from late enrolment found no differences (data not shown). One further explanation for the QoL differences between LACE and LAP-2 could also be that no LAVH was performed in the LACE trial, and all procedures were completed totally laparoscopically, whereas the majority of procedures were LAVH in the LAP-2 trial Therefore, our statistical analysis approach is not influenced by statistically significant differences in QoL values at baseline as seen in the subscale "physical functioning" in the LAP-2 trial (16) .
Past prospective studies have indicated that the laparoscopic approach is comparable to or better than the abdominal approach in terms of short-term outcomes such as complications, blood loss, and length of hospital stay (6, 8, 36) . TLH specifically has been shown to be advantageous for these outcomes in retrospective series (17, 37) and this has been confirmed in the present analysis, with a smaller proportion of patients randomised to TLH experiencing post-operative adverse events. Quicker recovery from surgery and freedom from postoperative adverse events will thus likely have contributed to better QoL outcomes in patients with TLH.
Limitations of our study include those frequently encountered by surgical trials. Blinding of patients and treatment team has not been attempted. Randomisation was well ahead of surgery and for ethical reasons patients had to be aware of the treatment they were to receive.
Recruitment for the study was conducted in hospitals well equipped to deal with patients after major abdominal surgery and the new laparoscopic technique.
In summary, the results of this randomised-controlled trial demonstrate that QoL recovery in endometrial cancer patients undergoing surgery by TLH is clinically and statistically significantly superior during the early and late post-operative phases, compared to QoL in those treated with TAH. The QoL findings are more pronounced than those of some earlier trials, most likely because the conversion rate from TLH to TAH was very low. Further follow-up of the patients in this trial will ascertain the equivalence of disease-free survival. 
